Global Parkinson's Disease Treatment: Market Report 2022: Market to Reach $6.7 Billion by 2027 - Levodopa / Carbidopa Segment is Projected to Record a 6.6% CAGR and Reach $2.4 Billion - ResearchAndMarkets.com
Levodopa / Carbidopa, one of the segments analyzed in the report, is projected to record a 6.6% CAGR and reach US$2.4 Billion by the end of the analysis period.
- Levodopa / Carbidopa, one of the segments analyzed in the report, is projected to record a 6.6% CAGR and reach US$2.4 Billion by the end of the analysis period.
- China, the world's second largest economy, is forecast to reach a projected market size of US$1.4 Billion by the year 2027 trailing a CAGR of 8.4% over the analysis period 2020 to 2027.
- Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$882.1 Million by the year 2027.
- In the global MAO-Inhibitors segment, USA, Canada, Japan, China and Europe will drive the 5.6% CAGR estimated for this segment.